Cancer biomarkers for susceptibility to treatment by almitrine
OwnerMichael David Forrestinventor
Life of this patent
Estimating the term…
Abstract
Biomarkers of cancer susceptibility/resistance to almitrine treatment are disclosed.
Claims23
A method to predict (give an indication of;
- give a probabilistic indication of) the susceptibility/responsiveness of a subject's cancer to almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) administration, comprising the steps of:
- i) obtaining (or starting with) a biological sample(s) from the subject;
- ii) ex vivo/in vitro, determining the mRNA and/or cDNA and/or protein expression level of one or more of SCAF11, RAPH1, DNAJC12, TMPRSS3, PTGS1, CASP2, ZNF766, ZNF277, TPK1, MYC, CBLL1, SORL1, SYT1, SUPV3L1, ILF2, HMX1, FABP6, KCNC3, CAMKK2, DDX49, LETMD1, ITGB5, RAB23 in the sample(s) obtained from the subject to obtain a value, or values, representing this level(s);
- and
- iii) comparing said expression level(s) to a reference expression level(s):
- comparing the value, or values, of the level(s) from step (ii) with a standard/reference value, or a set of standard/reference values, wherein this comparison predicts (gives an indication of;
- gives a probabilistic indication of) the subject's cancer's susceptibility/responsiveness to almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) administration.
A microarray chip comprising/containing a nucleic acid probe(s) for (i.e. a single-stranded nucleotide sequence(s) that is complimentary for/hybridisable to, preferably with ≥85% sequence identity to) mRNA and/or cDNA (and/or part(s) thereof, e.g. ≥15 consecutive nucleotides thereof) of one or more of SCAF11, RAPH1, DNAJC12, TMPRSS3, PTGS1, CASP2, ZNF766, ZNF277, TPK1, MYC, CBLL1, SORL1, SYT1, SUPV3L1, ILF2, HMX1, FABP6, KCNC3, CAMKK2, DDX49, LETMD1, ITGB5, RAB23.
A method of predicting (giving an indication of;
- giving a probabilistic indication of) whether a cancer, optionally inside a subject, is susceptible/responsive to almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) treatment by comparing whether its gene/mRNA/cDNA/protein expression of one or more of “GENE Q” is equal or higher (and/or substantially similar), and/or its gene/mRNA/cDNA/protein expression of one or more of “GENE Y” is equal or lower (and/or substantially similar), than a cancer(s) (optionally a cancer cell line[s]) known to be susceptible/responsive to almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) administration.
A method of treating a subject (e.g. a human subject) diagnosed with cancer comprising administering a therapeutically effective amount of almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) to the subject with a difference score determined from a cancer/tumor sample (optionally from a biopsy) from the subject;
- wherein the difference score is substantially similar to a difference score of a subject's cancer (e.g. a human subject) known to be sensitive/responsive to almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) administration;
- and/or
- wherein the difference score is substantially dissimilar to a difference score of a subject's cancer (e.g. a human subject) known to be resistant to almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) administration;
- and
- wherein the difference score is the difference between a level of expression of one or more “GENE Q” (if more than one “GENE Q”, their mean is taken and used) and a level of expression of one or more “GENE Y” (if more than one “GENE Y”, their mean is taken and used);
- optionally wherein the difference score is the difference between the level of expression of SCAF11 and the level of expression of RAPH1.
A method of treating a subject (e.g. a human subject) diagnosed with cancer comprising administering a therapeutically effective amount of almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) to the subject, wherein the subject's cancer has been predicted/determined to be responsive to almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) administration according to a method comprising:
- (a) contacting a cancer/tumor sample (optionally from a biopsy) from the subject, comprising nucleic acid molecules, with a device (optionally a microarray) comprising:
- (i) single-stranded nucleic acid molecules (optionally immobilized on a solid substrate) capable of specifically hybridizing with the nucleotides (e.g. mRNA and/or cDNA) of one or more of “GENE Q”;
- and
- (ii) single-stranded nucleic acid molecules (optionally immobilized on a solid substrate) capable of specifically hybridizing with the nucleotides (e.g. mRNA and/or cDNA) of one or more of “GENE Y”;
- and
- (b) detecting a level of expression of one or more of “GENE Q” and one or more of “GENE Y”;
- measuring hybridization between the one or more nucleic acid molecules from the sample and the single-stranded nucleic acid molecules of the device to detect a level of expression of one or more of “GENE Q” and one or more of “GENE Y”;
- and
- (c) calculating a difference score for the subject's cancer by subtracting the level of expression of one or more of “GENE Y” (if more than one “GENE Y”, their mean is taken and used) from the level of expression of one or more of “GENE Q” (if more than one “GENE Q”, their mean is taken and used);
- wherein the difference score is substantially similar to the difference score of a subject's cancer (e.g. a human subject) known to be sensitive/responsive to almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) administration;
- and/or
- wherein the difference score is substantially dissimilar to the difference score of a subject's cancer (e.g. a human subject) known to be resistant to almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) administration;
- optionally wherein the difference score is the difference between the level of expression of SCAF11 and the level of expression of RAPH1.
A method of treating a subject (e.g. a human subject) diagnosed with cancer, wherein their cancer has high/overexpressed MYC protein and/or nucleic acid expression, optionally wherein this greater MYC amount confers (or is at least associated/correlated with its) resistance (or decreased susceptibility) to a cancer treatment(s)/drug(s) {non-limiting e.g. imatinib/dasatinib/nilotinib/radotinib/bosutinib/ponatinib, or a salt thereof}, optionally wherein the cancer is AML or CML or NSCLC, comprising administering a therapeutically effective amount of almitrine (and/or a pharmaceutically-acceptable salt, solvate, hydrate or prodrug thereof) to the subject, optionally in co-therapy with the aforementioned cancer treatment(s)/drug(s) in this claim, optionally conferring synergistic anti-cancer activity.
Dependencies are inferred from the claim text.